Business Context and Reporting Period
Company: Upstream Bio, Inc. (Nasdaq: UPB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Upstream Bio is a clinical-stage biopharmaceutical company developing verekitug, a monoclonal antibody that targets the Thymic Stromal Lymphopoietin (TSLP) receptor. The company focuses on severe respiratory disorders, specifically severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). Verekitug is the only known antagonist in clinical development targeting the TSLP receptor.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Collaboration Revenue | $2,370 | $2,380 |
| Research & Development Expenses | $62,966 | $31,799 |
| General & Administrative Expenses | $17,168 | $10,695 |
| Net Loss | $(62,806) | $(20,537) |
| Cash, Cash Equivalents & Short-Term Investments | $470,500 | $109,800 |
| Accumulated Deficit | $(190,780) | $(127,974) |
Note: The company has no product revenue. Revenue is derived solely from a collaboration agreement with Maruho Co., Ltd. for research and development services.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $42.3 million (206%) from 2023 to 2024, primarily driven by a $31.2 million increase in R&D expenses and a $6.5 million increase in G&A expenses.
- R&D Expense Growth: R&D expenses doubled, reflecting the advancement of Phase 2 trials for severe asthma and CRSwNP, and the initiation of planning for a COPD Phase 2b trial. Direct costs for the asthma indication increased by $13.5 million.
- Liquidity Position: Cash and short-term investments increased significantly from $109.8 million to $470.5 million. This was driven by the October 2024 Initial Public Offering (IPO), which generated $268.8 million in net proceeds, and a Series B preferred stock closing that raised $149.9 million.
- Interest Income: Interest income rose to $12.1 million in 2024 from $4.2 million in 2023 due to higher cash balances and investment yields.
Guidance, Outlook, and Risks
Clinical Outlook and Milestones
- CRSwNP: Enrollment in the Phase 2 trial (VIBRANT) was completed in January 2025. Top-line data is expected in the second half of 2025.
- Severe Asthma: The Phase 2 trial (VALIANT) is ongoing. Top-line data is expected in the second half of 2026.
- COPD: Planning for a Phase 2b trial (VENTURE) has begun. The first patient is expected to be dosed in the second half of 2025.
Liquidity and Capital Resources
Management believes existing cash, cash equivalents, and short-term investments ($470.5 million as of Dec 31, 2024) are sufficient to fund operations and capital expenditures through 2027. The company expects to continue incurring significant losses as it advances clinical development.
Key Risks and Contingencies
- Single Product Candidate: The business depends entirely on the success of verekitug. Failure in clinical trials or regulatory approval would materially harm the company.
- Third-Party Dependence: The company relies on third parties for manufacturing (including WuXi Biologics) and clinical trial conduct. Supply chain disruptions or regulatory actions against manufacturers (e.g., potential U.S. legislation regarding Chinese biotechnology companies) pose significant risks.
- Regulatory Uncertainty: As a clinical-stage company, there is no guarantee of FDA or EMA approval. The novel mechanism of action (TSLP receptor antagonist) introduces unpredictability in the approval process.
- Intellectual Property: The company owns 12 patent families for verekitug, with key patents expiring between 2034 and 2045. However, patent protection is subject to legal challenges and varying international laws.
Investor Verification Checklist
- Cash Runway: Verify the $470.5 million cash balance and the management's projection of funding sufficiency through 2027 against actual burn rates.
- Clinical Trial Progress: Monitor enrollment rates and safety data for the ongoing Phase 2 trials in asthma and CRSwNP, and the initiation timeline for the COPD trial.
- Manufacturing Supply Chain: Assess the impact of geopolitical tensions and potential U.S. legislation (e.g., BIOSECURE Act) on the company's relationship with its primary contract manufacturer, WuXi Biologics.
- Revenue Model: Confirm the sustainability of the $2.4 million annual revenue from the Maruho collaboration and the lack of product revenue.
- Patent Portfolio: Review the status of the 12 patent families and potential challenges to the TSLP receptor targeting claims.